Mammograms: Are we overdiagnosing small tumors?

June 7, 2017
Credit: National Cancer Institute/public domain

An analysis of breast cancer data revealed that many small breast cancers have an excellent prognosis because they are inherently slow growing, according to Yale Cancer Center experts. Often, these cancers will not grow large enough to become significant within a patient's lifetime and subsequently early detection could lead to overdiagnosis, said the reseachers. In contrast, large tumors that cause most breast cancer deaths often grow so quickly that they become intrusive before they can be detected by screening mammography, they note.

The study, published June 8 in the New England Journal of Medicine, questions the value of .

"Our analysis explains both how mammography causes overdiagnosis and also why it is not more effective in improving outcomes for our . More importantly, it questions some of our fundamental beliefs about the value of early detection," said Donald R. Lannin, M.D., professor of surgery at Yale School of Medicine and lead author on the paper.

The research team analyzed invasive cancers diagnosed between 2001 and 2013 in the Surveillance, Epidemiology, and End Results (SEER) database and divided them into three prognostic groups based on biologic factors: grade, estrogen receptor (ER) status, and progesterone-receptor (PR) status. The three biologic categories were defined as favorable, intermediate, and unfavorable.

The team, which also included Shiyi Wang, M.D., assistant professor of epidemiology at Yale School of Public Health, then used the expected rate of overdiagnosis of 22% to model the types of breast cancers and patient age ranges that likely account for the majority of overdiagnosis. The results showed that most overdiagnosis occurred in older patients with biologically favorable, slow-growing tumors.

"Until now, we thought that the lead time, or time until a cancer becomes problematic for a patient, for most breast cancers was about three or four years. This paper shows that lead times vary widely depending on the tumor type. A large portion of aggressive cancers have a lead time of two years or less, whereas another large portion of breast cancers grow so slowly that the lead time is 15 to 20 years," Lannin explained.

"It is important that we educate physicians, patients, and the public on the indolent, slow-growing nature of some breast cancers. This knowledge will allow us to individualize treatment options, provide 'personalized medicine,' and avoid the major harms of , which can result in overtreatment and the anxiety and fear that a diagnosis causes," Lannin said.

Explore further: Breast MRI may lead to overdiagnosis for older women

Related Stories

Breast MRI may lead to overdiagnosis for older women

December 2, 2015
Magnetic resonance imaging (MRI) of the breast has become part of routine medical care for many women undergoing breast cancer surgery, but these highly sensitive tests might identify health problems that would not otherwise ...

Breast cancer screening associated with substantial overdiagnosis in Danish study

January 9, 2017
Breast cancer screening in Denmark was associated with a substantial increase in the incidence of nonadvanced tumors and DCIS but not with a reduction in the incidence of advanced tumors. The rate of overdiagnosis was also ...

Screening MRI benefits women at average risk of breast cancer

February 21, 2017
MRI screening improves early diagnosis of breast cancer in all women-not only those at high risk-according to a new study from Germany published online in the journal Radiology.

Agreement on best estimates of breast cancer overdiagnosis urgently needed to inform women

March 3, 2015
In 2012, prompted by increasing debate about overdiagnosis, an independent UK panel estimated that about 19% of breast cancers diagnosed among women invited to mammogram screening were in fact overdiagnosed (they would have ...

Many women shocked about breast screening overdiagnosis but would still go for a mammography

April 24, 2013
Women are surprised and shocked that breast screening can lead to 'overdiagnosis' of cancer, but would rather go for screening than take the risk of missing a cancer that could be treated, according to new research published ...

Public not being informed about dangers of medical overdiagnosis

May 20, 2015
A national survey reveals that only one in ten Australians report being told about the risk of overdiagnosis by their doctors, according to research published today in the scientific journal PLOS ONE.

Recommended for you

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Suicide molecules kill any cancer cell

October 19, 2017
Small RNA molecules originally developed as a tool to study gene function trigger a mechanism hidden in every cell that forces the cell to commit suicide, reports a new Northwestern Medicine study, the first to identify molecules ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Fundamental research enhances understanding of major cancer gene

October 19, 2017
New research represents a promising step towards better understanding of a key cancer gene. A long-running collaboration between researchers at the Babraham Institute, Cambridge and the AstraZeneca IMED Biotech Unit reveals ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.